@article{ref1,
title="Are we repeating mistakes of the past? A review of the evidence for esketamine",
journal="British journal of psychiatry",
year="2021",
author="Horowitz, Mark A. and Moncrieff, Joanna",
volume="219",
number="5",
pages="614-617",
abstract="Esketamine has been licensed for 'treatment-resistant depression' in the USA, UK and Europe. Licensing trials did not establish efficacy: two trials were negative, one showed a statistically significant but clinically uncertain effect, and a flawed discontinuation trial was included, against Food and Drug Administration precedent. Safety signals - deaths, including suicides, and bladder damage - were minimised.<p /><p>Language: en</p>",
language="en",
issn="0007-1250",
doi="10.1192/bjp.2020.89",
url="http://dx.doi.org/10.1192/bjp.2020.89"
}